Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

abstract：:Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...

journal_title：Current hematologic malignancy reports

authors： Helgason GV,Young GA,Holyoake TL

更新日期：2010-04-01 00:00:00

abstract：:Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...

journal_title：Current hematologic malignancy reports

authors： Karp Leaf R,Cho HJ,Avigan D

更新日期：2015-12-01 00:00:00

abstract：:The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...

journal_title：Current hematologic malignancy reports

authors： La Rosée P,Hochhaus A

更新日期：2008-04-01 00:00:00

abstract：:Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...

journal_title：Current hematologic malignancy reports

authors： Barber NA,Bierman PJ

更新日期：2012-09-01 00:00:00

abstract：PURPOSE OF REVIEW:Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival...

journal_title：Current hematologic malignancy reports

authors： Torka P,Barth M,Ferdman R,Hernandez-Ilizaliturri FJ

更新日期：2019-10-01 00:00:00

abstract：:Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...

journal_title：Current hematologic malignancy reports

authors： Chung CG,Poligone B

更新日期：2015-12-01 00:00:00

abstract：PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...

journal_title：Current hematologic malignancy reports

authors： Hilal T,Munoz J

更新日期：2020-08-01 00:00:00

abstract：:Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic maligna...

journal_title：Current hematologic malignancy reports

authors： Sethi TK,Basdag B,Bhatia N,Moslehi J,Reddy NM

更新日期：2017-06-01 00:00:00

abstract：PURPOSE OF REVIEW:Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are ...

journal_title：Current hematologic malignancy reports

authors： Ghione P,Moskowitz AJ,De Paola NEK,Horwitz SM,Ruella M

更新日期：2018-12-01 00:00:00

abstract：:The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors,...

journal_title：Current hematologic malignancy reports

authors： Pinnix CC,Andraos TY,Milgrom S,Fanale MA

更新日期：2017-06-01 00:00:00

abstract：PURPOSE OF REVIEW:The recent development of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30-positive cells, has led to therapeutic advances in the treatment of T cell lymphomas. In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and...

journal_title：Current hematologic malignancy reports

authors： Shea L,Mehta-Shah N

更新日期：2020-02-01 00:00:00

abstract：PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...

journal_title：Current hematologic malignancy reports

authors： Hakki M

更新日期：2020-04-01 00:00:00

abstract：:A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...

journal_title：Current hematologic malignancy reports

authors： Finazzi G,De Stefano V,Barbui T

更新日期：2013-12-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a complex clonal disorder. The disease is characterized by chromosomal and molecular abnormalities that propagate and expand the abnormal clone(s). The main goal of therapy is to achieve and ultimately maintain a complete remission. In the younger AML patient (less than 60 years of age)...

journal_title：Current hematologic malignancy reports

authors： Fernandez HF

更新日期：2016-10-01 00:00:00

abstract：PURPOSE OF REVIEW:This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma. RECENT FINDINGS:The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1,...

journal_title：Current hematologic malignancy reports

authors： Havard R,Stephens DM

更新日期：2018-12-01 00:00:00

abstract：:The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the ...

journal_title：Current hematologic malignancy reports

authors： Pemmaraju N,Gupta V,Mesa R,Thompson MA

更新日期：2015-12-01 00:00:00

abstract：:Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...

journal_title：Current hematologic malignancy reports

authors： Dhawan R,Marks DI

更新日期：2017-04-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. Th...

journal_title：Current hematologic malignancy reports

authors： Gergis U,Wissa U

更新日期：2010-01-01 00:00:00

abstract：:Just as a pawnshop owner who is unable to distinguish a genuine Rolex™ watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic myelodysplastic syndromes (MDS) and conditions resembling MDS risks misinforming or harming patients. This review summarizes minimal criter...

journal_title：Current hematologic malignancy reports

authors： Steensma DP

更新日期：2012-12-01 00:00:00

abstract：PURPOSE OF REVIEW:This review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease. RECENT FINDINGS:Over the last decade, the routine use of HCT as consolidative t...

journal_title：Current hematologic malignancy reports

authors： Hunter BD,Chen YB

更新日期：2020-02-01 00:00:00

abstract：:Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...

journal_title：Current hematologic malignancy reports

authors： Pieters R

更新日期：2009-07-01 00:00:00

abstract：:Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...

journal_title：Current hematologic malignancy reports

authors： Forstpointner R,Dreyling M

更新日期：2011-12-01 00:00:00

abstract：:Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...

journal_title：Current hematologic malignancy reports

authors： Faderl S,Wierda W,Keating MJ

更新日期：2006-12-01 00:00:00

abstract：:The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...

journal_title：Current hematologic malignancy reports

authors： Casasnovas RO,Meignan M,Berriolo-Riedinger A,Itti E,Huglo D,Haioun C,Morschhauser F

更新日期：2012-09-01 00:00:00

abstract：:The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by gen...

journal_title：Current hematologic malignancy reports

authors： Them NC,Kralovics R

更新日期：2013-12-01 00:00:00

abstract：PURPOSE OF REVIEW:The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS:Recent studi...

journal_title：Current hematologic malignancy reports

authors： Darrah JM,Herrera AF

更新日期：2018-10-01 00:00:00

abstract：:Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

journal_title：Current hematologic malignancy reports

authors： Buckley SA,Walter RB

更新日期：2015-06-01 00:00:00

abstract：:Measuring the quality of care for patients with chronic cancers is difficult, especially for heterogeneous malignancies such as the myelodysplastic syndromes (MDS). Recent work suggests that improvements may be needed in the quality of diagnostic, treatment, and end-of-life care for patients with these syndromes. More...

journal_title：Current hematologic malignancy reports

authors： Frosch ZA,Abel GA

更新日期：2016-12-01 00:00:00

abstract：PURPOSE OF REVIEW:Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. RECENT FINDINGS:Dedicated geriatric assessment tools can aid the clini...

journal_title：Current hematologic malignancy reports

authors： Koll TT,Rosko AE

更新日期：2018-06-01 00:00:00

abstract：PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...

journal_title：Current hematologic malignancy reports

authors： Bangerter LR,Griffin JM,Langer S,Hasan B,Kim WS,Murad MH,Khera N

更新日期：2018-06-01 00:00:00